We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Radioembolization Microspheres Treat Hepatocellular Carcinoma

By MedImaging International staff writers
Posted on 29 Mar 2021
Print article
Image: A vial of TheraSphere contains millions of microscopic glass beads containing yttrium (Photo courtesy of Boston Scientific)
Image: A vial of TheraSphere contains millions of microscopic glass beads containing yttrium (Photo courtesy of Boston Scientific)
A selective internal radiation therapy (SIRT) platform delivers radioactive glass microspheres directly to liver tumors, with minimal exposure to surrounding healthy tissue.

Boston Scientific (Natick, MA, USA) TheraSphere treatment is a low toxicity SIRT comprised of millions of microscopic glass beads containing yttrium (Y-90) that are delivered to a Hepatocellular Carcinoma (HCC) through a catheter placed into the hepatic artery, which provides the main blood supply to the HCC. The microspheres, which are unable to traverse the tumor vasculature, are embolized within the tumor, exerting a local beta radiation radiotherapeutic effect, as the average range of the radiation in tissue is 2.5 mm, with a maximum range less than one centimeter.

TheraSphere is available in three dose sizes, each supplied with an administration set consisting of a single use, pre-assembled vial with inlet and outlet lines that facilitate infusion of the microspheres to the catheter. Each milligram of TheraSphere contains between 22,000 and 73,000 microspheres of Y-90. The treatment does not require hospitalization, and is typically performed as an outpatient procedure in as little as an hour. TheraSphere has been approved by the FDA after almost 20 years of humanitarian exemption device (HDE).

“The FDA approval will expand access to TheraSphere, which has demonstrated improvement in both survivability and quality of life through 20 years of clinical trials and real-world outcomes in the more than 70,000 patients globally,” said Peter Pattison, president of interventional oncology and peripheral interventions at Boston Scientific. “We expect to continue to focus our efforts on bringing this treatment to more patients, as well as further investigating the therapy for different cancer segments, including prostate and brain.”

As healthy liver tissue is mainly perfused by the portal vein, and most liver malignancies derive their blood supply from the hepatic artery, trans-arterial radioembolization (TARE) using radioactive Yttrium radioactive glass microspheres can be selectively administered to the tumors. The microspheres lodge in the small vessels of the tumor (embolization), emitting localized RT to targeted segments, results in tissue necrosis. The Y-90, with a half-life of 3.85 days, decays to Zirconium-90.

Related Links:
Boston Scientific

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
C-Arm with FPD
Digiscan V20 / V30
Ultrasound Needle Guide
Ultra-Pro II
Oncology Information System
RayCare

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

General/Advanced Imaging

view channel
Image: The Tyche machine-learning model could help capture crucial information. (Photo courtesy of 123RF)

New AI Method Captures Uncertainty in Medical Images

In the field of biomedicine, segmentation is the process of annotating pixels from an important structure in medical images, such as organs or cells. Artificial Intelligence (AI) models are utilized to... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.